Literature DB >> 10460096

Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.

M P Hawken1, D W Muhindi.   

Abstract

There is now strong evidence from several randomized controlled trials for the efficacy of preventive therapy in the prevention of tuberculosis in tuberculin skin test positive persons infected with the human immunodeficiency virus (HIV). The World Health Organization and the International Union Against Tuberculosis and Lung Disease recommend preventive therapy for tuberculin skin test positive, HIV-infected persons who do not have active tuberculosis. While implementation of preventive therapy is manageable in industrialised countries because it is affordable and the infrastructure is in place to screen, treat and monitor patients on a regular basis, its implementation in developing countries presents several problems. Feasibility issues such as identification of large numbers of HIV-infected persons, exclusion of active tuberculosis, identification of those most likely to benefit, supervision of preventive therapy and monitoring of adverse drug reactions need to be resolved before tuberculosis preventive therapy can be introduced on a larger scale in developing countries. Possible sites for implementation of a tuberculosis preventive therapy service include voluntary counselling and testing centres for HIV and occupational health clinics for military personnel, hospital or company workers. Feasibility studies need to be carried out to address these issues in developing countries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460096

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa.

Authors:  D Guwatudde; S M Debanne; M Diaz; C King; C C Whalen
Journal:  Prev Med       Date:  2004-11       Impact factor: 4.018

2.  Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.

Authors:  Krishna P Reddy; Mark F Brady; Robert H Gilman; Jorge Coronel; Marcos Navincopa; Eduardo Ticona; Gonzalo Chavez; Eduardo Sánchez; Christian Rojas; Lely Solari; Jorge Valencia; Yvett Pinedo; Carlos Benites; Jon S Friedland; David A J Moore
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

Review 3.  Managing tuberculosis and HIV in sub-Sahara Africa.

Authors:  Umesh G Lalloo; Sandy Pillay
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

4.  A systematic review of economic evaluations of chemoprophylaxis for tuberculosis.

Authors:  Shraddha Chavan; David Newlands; Cairns Smith
Journal:  J Trop Med       Date:  2011-11-01

5.  Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study.

Authors:  Mesele Mindachew; Amare Deribew; Peter Memiah; Sibhatu Biadgilign
Journal:  Pan Afr Med J       Date:  2014-01-17

6.  Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria.

Authors:  Olabanjo Okunlola Ogunsola; Oluseye Ajayi; Omobola Ojo; Oluwatomisin Adeyeye; Yewande Akinro; Oluwabunmi Oke; Adefolake Adebare Adurogbola; Olalere Olajide
Journal:  Pan Afr Med J       Date:  2019-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.